Covidien (COV) - FREE Research Report

Almeida Jose E who is President and Chief Executive at Covidien sold 17,500 shares at $66.00 on Nov. 15, 2013. Following this transaction, the President and Chief Executive owned 200,566 shares meaning that the stake was reduced by 8.03% with the 17,500 share transaction.

Lannum Coleman N III who is Vice President at Covidien sold 5,707 shares at $65.49 on Nov. 15, 2013. Following this transaction, the Vice President owned 7,374 shares meaning that the stake was reduced by 43.63% with the 5,707 share transaction.

Green Eric C who is Vice President at Covidien sold 7,392 shares at $65.00 on Nov. 15, 2013. Following this transaction, the Vice President owned 12,726 shares meaning that the stake was reduced by 36.74% with the 7,392 share transaction.

Dockendorff Charles J who is EVP & Chief Financial Officer at Covidien sold 39,397 shares at $66.22 on Nov. 15, 2013. Following this transaction, the EVP & Chief Financial Officer owned 111,273 shares meaning that the stake was reduced by 26.15% with the 39,397 share transaction.

The shares most recently traded at $67.15, up $0.93, or 1.38% since the insider transaction. Historical insider transactions for Covidien go as follows:

  • 4-Week # shares sold: 39,709
  • 12-Week # shares sold: 43,149
  • 24-Week # shares sold: 59,740

The average volume for Covidien has been 2.2 million shares per day over the past 30 days. Covidien has a market cap of $30.4 billion and is part of the health care sector and health services industry. Shares are up 14.44% year to date as of the close of trading on Friday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The stock currently has a dividend yield of 1.96%. The company has a P/E ratio of 17.8. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on COV - FREE

TheStreet Quant Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

3 Stocks Driving The Financial Sector Higher

3 Stocks Improving Performance Of The Real Estate Industry

American Realty Capital Properties (ARCP) Stock Up After Meister Names it 'Best Idea'

Today's Stocks Driving Success For The Real Estate Industry

3 Stocks Advancing The Real Estate Industry